Clinical Trial Update: A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial update evaluating donanemab, RG6289, or their combination in individuals with PSEN1 E280A mutation-associated autosomal-dominan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Donanemab (donanemab)
• RG6289

Snippet

Sponsor: Banner Health | Conditions: Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING